Bullish on the prospects of API business: Aditya Khemka Prefer small and midcap pharma companies
With over 50% gain, the pharma sector was one of the best performing indices of 2020. according to Aditya Khemka, fund manager of Incred AMC, multiples of pharma in-line with historic average and roe consistently improving. Khemka prefers small & midcap pharma companies over large caps. he is bullish on the prospects of API business and believes chronic businesses will continue to perform well. Biosimilars are at a nascent stage of growth and there is plenty of scope for growth in biosimilars business, it is an unchartered territory at the moment and that s why makes more sense for pe investors to be in biosimilars in India, I don t know if Indian firms can compete in biologics, he said.